These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

500 related articles for article (PubMed ID: 34441364)

  • 1. Impact of 18F-FDG PET/CT on Clinical Management of Suspected Radio-Iodine Refractory Differentiated Thyroid Cancer (RAI-R-DTC).
    Lodi Rizzini E; Repaci A; Tabacchi E; Zanoni L; Vicennati V; Cavicchi O; Pagotto U; Morganti AG; Fanti S; Monari F
    Diagnostics (Basel); 2021 Aug; 11(8):. PubMed ID: 34441364
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 18F-FDG PET/CT concurrent with first radioiodine post-therapeutic scan in high risk differentiated thyroid cancer: a useful tool or just an expensive diversion?
    Rizzo A; Perotti G; Zagaria L; Lanni V; Racca M; Palestini N; Salvatori M
    Q J Nucl Med Mol Imaging; 2023 Jun; 67(2):158-166. PubMed ID: 35238517
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [18F]-FDG-PET/CT Correlates With the Response of Radiorefractory Thyroid Cancer to Lenvatinib and Patient Survival.
    Valerio L; Guidoccio F; Giani C; Tardelli E; Puccini G; Puleo L; Minaldi E; Boni G; Elisei R; Volterrani D
    J Clin Endocrinol Metab; 2021 Jul; 106(8):2355-2366. PubMed ID: 33901285
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lactate Dehydrogenase A is Associated with Elevated FDG Metabolism, Radioiodine Non-avidity, and Poor Prognosis in Differentiated Thyroid Cancer.
    Tian T; Dai H; Zhang M; Su M; Chen X; Huang R
    Acad Radiol; 2024 Oct; 31(10):4011-4020. PubMed ID: 38866688
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic Role of 2-[
    Albano D; Dondi F; Mazzoletti A; Bellini P; Rodella C; Bertagna F
    Diagnostics (Basel); 2021 Nov; 11(12):. PubMed ID: 34943426
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic Value of FDG-PET/CT Metabolic Parameters in Metastatic Radioiodine-Refractory Differentiated Thyroid Cancer.
    Manohar PM; Beesley LJ; Bellile EL; Worden FP; Avram AM
    Clin Nucl Med; 2018 Sep; 43(9):641-647. PubMed ID: 30015659
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of
    Piccardo A; Trimboli P; Puntoni M; Foppiani L; Treglia G; Naseri M; Bottoni GL; Massollo M; Sola S; Ferrarazzo G; Bruzzone M; Catrambone U; Arlandini A; Paone G; Ceriani L; Cabria M; Giovanella L
    Thyroid; 2019 Apr; 29(4):549-556. PubMed ID: 30864903
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of early 18F-FDG PET/CT in therapeutic management and ongoing risk stratification of high/intermediate-risk thyroid carcinoma.
    Triviño Ibáñez EM; Muros MA; Torres Vela E; Llamas Elvira JM
    Endocrine; 2016 Mar; 51(3):490-8. PubMed ID: 26224589
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Diagnostic Performance of [
    Ventura D; Dittmann M; Büther F; Schäfers M; Rahbar K; Hescheler D; Claesener M; Schindler P; Riemann B; Seifert R; Roll W
    J Nucl Med; 2024 Feb; 65(2):192-198. PubMed ID: 38164565
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Correlation of 18F-FDG PET/CT findings with histopathological results in differentiated thyroid cancer patients who have increased thyroglobulin or antithyroglobulin antibody levels and negative 131I whole-body scan results.
    Ozkan E; Aras G; Kucuk NO
    Clin Nucl Med; 2013 May; 38(5):326-31. PubMed ID: 23486319
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Relationship between clinicopathologic factors and FDG avidity in radioiodine-negative recurrent or metastatic differentiated thyroid carcinoma.
    Ha LN; Iravani A; Nhung NT; Hanh NTM; Hutomo F; Son MH
    Cancer Imaging; 2021 Jan; 21(1):8. PubMed ID: 33413689
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical role of 18F-FDG PET/CT for detection of radioactive iodine refractory differentiated thyroid cancer.
    Tang X; Shi L; Zhao Z; Wang J; Yang R; Huang Y; Tang J; Chen Z; Wang F
    Medicine (Baltimore); 2023 Jun; 102(24):e33878. PubMed ID: 37327310
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The value of [18F]FDG PET/CT in avoiding overtreatment of 131l avidity pulmonary metastasis of differentiated thyroid cancer.
    Xu Z; Li C; Feng F; Wu S; Wang H; Fu H
    Endokrynol Pol; 2023 Aug; ():. PubMed ID: 37577994
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Using 18F-FDG-PET/CT Metrics to Predict Survival in Ra-Dio-Iodine Refractory Thyroid Cancers.
    Roy M; Edet-Sanson A; Lefebvre H; Vera P; Decazes P
    Diagnostics (Basel); 2022 Sep; 12(10):. PubMed ID: 36292070
    [TBL] [Abstract][Full Text] [Related]  

  • 15. FDG PET/CT for the early prediction of RAI therapy response in patients with metastatic differentiated thyroid carcinoma.
    Kang SY; Bang JI; Kang KW; Lee HY; Chung JK
    PLoS One; 2019; 14(6):e0218416. PubMed ID: 31237886
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of 18F-Fluorodeoxyglucose Positron Emission Tomography in patients with suspected recurrence or metastatic differentiated thyroid carcinoma with elevated serum thyroglobulin and negative I-131 whole body scan.
    Trybek T; Kowalska A; Lesiak J; Młynarczyk J
    Nucl Med Rev Cent East Eur; 2014; 17(2):87-93. PubMed ID: 25088108
    [TBL] [Abstract][Full Text] [Related]  

  • 17.
    Parihar AS; Mittal BR; Kumar R; Shukla J; Bhattacharya A
    Thyroid; 2020 Apr; 30(4):557-567. PubMed ID: 31870227
    [No Abstract]   [Full Text] [Related]  

  • 18. Prognostic role of pretreatment 18F-FDG PET/CT in primary brain lymphoma.
    Albano D; Bertoli M; Battistotti M; Rodella C; Statuto M; Giubbini R; Bertagna F
    Ann Nucl Med; 2018 Oct; 32(8):532-541. PubMed ID: 29982990
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic role of baseline 18F-FDG PET/CT metabolic parameters in Burkitt lymphoma.
    Albano D; Bosio G; Pagani C; Re A; Tucci A; Giubbini R; Bertagna F
    Eur J Nucl Med Mol Imaging; 2019 Jan; 46(1):87-96. PubMed ID: 30276438
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PET/CT in the management of differentiated thyroid cancer.
    Zampella E; Klain M; Pace L; Cuocolo A
    Diagn Interv Imaging; 2021 Sep; 102(9):515-523. PubMed ID: 33926848
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.